Loading stock…

Sichuan Kelun Pharmaceutical Co., Ltd. (002422) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Sichuan Kelun Pharmaceutical Co., Ltd.

002422Market cap $9.20BPrice $5.9

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

Manufactures generic drugs, IV infusion fluids, and antibiotics for Chinese hospitals, plus licenses cancer immunotherapies to global pharma giants. Its ADC and PD-1 pipeline deals with Merck have made it one of China's top biotech licensing earners.

In Bastion Portfolios?

52W Return+22%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-1%2

Revenue Forecast

Rev CAGR (1y)+11%6

Rev CAGR (3y)+10%7

Rev CAGR (5y)+8%7

Earnings Forecast

EPS Growth Y+1-13%3

EPS Growth Y+2+62%10

EPS Growth Y+3+29%8

Quality

Margins

EBIT Margin8%4

Net Income Margin10%6

Free Cash Flow Margin12%6

Debt

Net Debt/EBITDA-1.710

Efficiency

ROE8%4

ROA5%6

Earnings Stability77

GEAR+STRONG67

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)137

P/E Ratio (Forward 3y)213

P/BV2.56

EV Multiples

EV/EBITDA Fwd163

EV/EBIT Fwd233

Yield

Free Cash Flow Yield3.7%5

Dividend Yieldna–

Momentum

Short term

1 month return-4%5

3 month return-9%4

YTD return+34%9

Mid term

Price vs 52wHigh75%4

1 year return+9%6

Long term

3 year return+43%5

5 year return+136%8

Risk Shield

Price Risk

Beta0.010

Volatility48%3

Free Cash Flow

Free Cash Flow Margin12%6

Free Cash Flow Yield3.7%5

Quality

ROCE5%3

Earnings Stability77

Net Debt/EBITDA-1.710

02Growth

Is it actually growing, and how fast?

002422Sichuan Kelun Pharmaceutical Co.

Revenue FY25$2.6B

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%2

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-13%3

EPS growth, FY27E+62%10

EPS growth, FY28E+29%8

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

After shrinking over the last 3 years, revenue is set to grow 10%/yr from here.

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Earnings are set to grow faster than sales (EPS about 29%/yr vs revenue 10%/yr), so margins should widen. One year dips: EPS falls 13% next year.

WEAKNESSES

Revenue fell 1%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

002422Sichuan Kelun Pharmaceutical Co.

Total return Current196%

Price return Current154%

MOMENTUM RATING↗

AVERAGE41 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-9%4

YTD return+34%9

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+9%6

3-year return+43%5

5-year return+136%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +43% over three years and +136% over five, ahead of 60% of the market.

Strong recent results. The stock is outperforming so far this year (+34%).

WATCH

It's up 9% over the past year, but 25% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-4%) and over three months (-9%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Sichuan Kelun Pharmaceutical Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

002422Sichuan Kelun Pharmaceutical Co.

Revenue FY25$2.6B

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-1%2

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-13%3

EPS growth, FY27E+62%10

EPS growth, FY28E+29%8

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

After shrinking over the last 3 years, revenue is set to grow 10%/yr from here.

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Earnings are set to grow faster than sales (EPS about 29%/yr vs revenue 10%/yr), so margins should widen. One year dips: EPS falls 13% next year.

WEAKNESSES

Revenue fell 1%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

002422Sichuan Kelun Pharmaceutical Co.

Total return Current196%

Price return Current154%

MOMENTUM RATING↗

AVERAGE41 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return-9%4

YTD return+34%9

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+9%6

3-year return+43%5

5-year return+136%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +43% over three years and +136% over five, ahead of 60% of the market.

Strong recent results. The stock is outperforming so far this year (+34%).

WATCH

It's up 9% over the past year, but 25% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-4%) and over three months (-9%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Sichuan Kelun Pharmaceutical Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community